Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1987-03-02
1988-09-13
Friedman, Stanley J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31505
Patent
active
047710535
ABSTRACT:
Gepirone and its pharmaceutically acceptable salts are useful in alleviation of certain primary depressive disorders, such as major depression with melancholia and atypical depression.
REFERENCES:
patent: 4423049 (1983-12-01), Temple
"Annual Reports in Medicinal Chemistry", vol. 21, pp. 15,43 (3/3) (1986).
Eison et al., Iuphar. Abstract, (London): 2018 (1984) (3/8).
Eison et al., Neuroscience Abstract 10:259 (1984) (3/9).
Eison et al., Eur. J. Pharmacol., 111:389-392 (1985) (3/10).
Eison et al., Drugs of the Future, 10:456-457 (1985) (3/11).
Eison et al., Neuroscience Abstract, 11:186 (1985) (3/14).
Schweizer et al., Psychopharmacol. Bull., 22:183-185 (1986) (7/4).
"Open Trial of Gepirone in the Treatment of Major Depressive Disorder" by J. D. Amsterdam et al., Current Therapeutic Research, 41/2:185-194 (1987).
Cott Jerry M.
Kurtz Neil
Robinson Donald S.
Bristol-Myers Company
Friedman Stanley J.
Ryan Richard P.
LandOfFree
Method for alleviation of primary depressive disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for alleviation of primary depressive disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for alleviation of primary depressive disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-807141